What the Study Reported
Three years after lecanemab became the first anti-amyloid antibody granted traditional FDA approval, its manufacturers have released data on how it has performed outside a clinical trial.
Eisai and Biogen announced on July 14 that in the Lecanemab in Early Alzheimer's Disease study, known as LEADER, nearly 83 percent of enrolled patients with early Alzheimer's disease remained stable or improved while receiving the drug over an average of 17 months. The companies reported that 75.9 percent remained stable and 6.6 percent improved, with results consistent across sex, race, ethnicity and APOE genotype.
The data were presented at the Alzheimer's Association International Conference in London in a session titled "Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings."
LEADER is described as a three-year multicenter retrospective study designed to examine utilization, treatment persistence, transition to maintenance therapy, safety, and cognitive and functional outcomes. The presentation also covered maintenance dosing given intravenously every four weeks and the first reported findings on at-home subcutaneous administration.
Why the Study Was Designed This Way
Real-world evidence exists to answer a question trials cannot, and understanding that question makes the result easier to read correctly.
CLARITY-AD, the phase 3 trial that earned lecanemab its approval in July 2023, enrolled 1,795 participants who met strict eligibility criteria. Trial populations are typically younger, healthier, and less medically complex than the patients who eventually receive a drug in practice. They are also less racially and ethnically diverse.
LEADER draws from actual clinical practice across multiple U.S. sites, tracking patients who are more diverse, older and medically more complex than the CLARITY-AD population, as Techtimes described in previewing the conference. Questions about who actually starts the drug, who stays on it, how infusion schedules hold up in community settings and what happens with monitoring are legitimate and cannot be answered from a controlled trial.
That is the value of this kind of study. It is also the source of its limits.
What a Retrospective Abstract Can and Cannot Establish
This is where the reporting has to be careful, because the headline figure is easy to misread.
LEADER is retrospective, meaning investigators looked back at records of patients who had already received treatment. It has no control group. Nobody in this study went untreated for comparison, so there is no way to know what would have happened to the same patients without the drug.
That matters enormously for a figure like "83 percent stable or improved." Early Alzheimer's disease progresses at variable rates, and some patients decline slowly over 17 months regardless of treatment. Without a comparator, stability cannot be attributed to the drug. The finding is a description of what happened, not a demonstration of why.
The definition of "stable" also carries weight that the announcement does not unpack. The threshold used, the instrument used to measure it, and how missing data were handled all shape that percentage, and none of those details are available in a press announcement.
The 17-month average is worth noticing alongside the three-year framing. The study period spans three years post-approval, but the average treatment duration analyzed is well under half that.
Selection effects run through retrospective designs. Patients who tolerate a drug and can manage biweekly infusions stay on it and appear in follow-up. Patients who discontinue early, experience amyloid-related imaging abnormalities, or cannot sustain the logistics may be underrepresented in outcome analyses.
Finally, this was presented in a Developing Topics session, which is a conference abstract format, and it has not been published in a peer-reviewed journal. The study was conducted by the drug's manufacturers.
The Counterargument in the Literature
Independent assessments of this drug class have reached notably different conclusions, and readers deserve to know that.
A Cochrane Review of anti-amyloid Alzheimer's drugs concluded that these therapies are not clinically effective, a finding that arrived in the same period as the LEADER presentation and that Techtimes framed as the backdrop for the conference. Cochrane reviews synthesize randomized evidence and apply strict thresholds for clinical meaningfulness, which is a different exercise from describing outcomes in a treated cohort.
The core dispute is whether the effect sizes seen in randomized trials, which were statistically significant, are large enough for patients and families to notice. That question is not settled by a study without a control group, and a company-sponsored abstract does not resolve it.
None of this makes LEADER worthless. It makes it evidence about implementation rather than evidence about efficacy.
What Patients and Families Should Take From It
For households weighing this treatment, the practical picture is unchanged by this announcement.
Lecanemab is approved for early Alzheimer's disease, meaning mild cognitive impairment due to Alzheimer's or mild Alzheimer's dementia, and requires confirmed amyloid pathology. It carries a risk of amyloid-related imaging abnormalities, which requires MRI monitoring on a defined schedule, and APOE4 genotype affects that risk. Those facts belong at the center of any conversation with a neurologist.
The delivery burden is easing. The FDA approved a once-weekly subcutaneous autoinjector formulation on July 13, 2026, for patients starting treatment, with commercial launch expected in late August through specialty pharmacy.
Anyone considering treatment should ask their clinician what magnitude of benefit is realistically expected, what the monitoring schedule involves, what would trigger stopping, and what the total out-of-pocket cost will be, including imaging.
MedicalDaily will report peer-reviewed publication of the LEADER data, any independent real-world analyses, and further findings on subcutaneous administration.
Frequently Asked Questions
What did LEADER find? That nearly 83 percent of enrolled early Alzheimer's patients remained stable, at 75.9 percent, or improved, at 6.6 percent, over an average of 17 months on lecanemab.
Is this a clinical trial? No. It is a retrospective real-world study drawing on records from U.S. clinical practice, with no control group.
Has it been peer reviewed? No. It was presented as a conference abstract at AAIC 2026 and has not been published in a peer-reviewed journal.
Does it prove the drug works? No. Without an untreated comparison group, stability over 17 months cannot be attributed to the drug.
Why run a study like this at all? To learn how a drug performs in older, more diverse and medically complex patients than trials enroll, and to track persistence, monitoring and safety in practice.
Who paid for it? Eisai and Biogen, the companies that co-commercialize lecanemab.
What should families ask a neurologist? Expected magnitude of benefit, the MRI monitoring schedule, ARIA risk including APOE4 status, what would trigger stopping, and total out-of-pocket cost.
